Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer.
Journal Information
Full Title: Technol Cancer Res Treat
Abbreviation: Technol Cancer Res Treat
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article."
Funding Disclosure
Evidence found in paper:
"Funding: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was financially supported by the NHC Key Laboratory of Nuclear Technology Medical Transformation (Mianyang Central Hospital) (grant nos. 2022HYX003)."
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025